Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PSTV files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsPlus Therapeutics establishes up to $17.35M at-the-market equity offering facility
Filed June 5, 2026 · Period ending June 1, 2026 · ~1 min read
Key Changes
-
high
Company can now sell up to $17.35 million of common stock directly on Nasdaq through Canaccord Genuity as sales agent, with no obligation to sell any shares. Sales will occur at the company's discretion based on market conditions.
Item 1.01 verify on EDGAR → -
medium
Proceeds will be used for general corporate purposes and working capital, providing flexibility but no specific allocation to drug development programs or clinical trials.
Item 1.01 verify on EDGAR → -
medium
Company will pay 3% commission on gross proceeds plus $75,000 in expenses to Canaccord Genuity. Sales cannot begin until SEC declares the June 2 Form S-3 registration statement effective.
Item 1.01 verify on EDGAR →
Summary
Plus Therapeutics has established an at-the-market equity offering facility allowing it to raise up to $17.35 million by selling common stock directly on the Nasdaq Capital Market through broker Canaccord Genuity.
Unlike traditional stock offerings that happen all at once, this facility lets the company sell shares gradually over time at prevailing market prices, providing financing flexibility without immediate dilution. Retail shareholders should understand this creates potential dilution risk—the company can issue new shares whenever it chooses, which would reduce existing shareholders' ownership percentage.
The broad "general corporate purposes" language for proceeds means investors won't know specifically how the capital will be deployed, whether for clinical trials, operations, or other needs. The company has no obligation to use the full facility. Watch for Form 424B5 prospectus supplements, which the company must file each time it actually sells shares under this agreement. These filings will reveal the timing, price, and amount of actual dilution as it occurs.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On June 1, 2026, Plus Therapeutics, Inc. (the “Company”) entered into an Equity Distribution Agreement (the “Distribution Agreement”) with Canaccord Genuity LLC (the “Agent”), pursuant to which the Company may issue and sell, from time to time (the “Offering”), shares of its common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $17,350,000 (the “Shares”), depending on market demand, with the Agent acting as an agent for sales.
The company established an at-the-market equity offering facility allowing it to sell up to $17.35 million of common stock through Canaccord Genuity as sales agent. Sales will be made directly on the Nasdaq Capital Market at the company's discretion, with no obligation to sell any shares. The company will pay a 3% commission on gross proceeds plus $75,000 in expense reimbursement.
Added in current filing · verify on EDGAR →
The Company intends to use the net proceeds from this offering for general corporate purposes and for working capital.
Net proceeds from any stock sales will be used for general corporate purposes and working capital. This is a broad, non-specific use of proceeds typical for at-the-market offerings, providing the company flexibility in capital allocation.
Added in current filing · verify on EDGAR →
Any sales of Shares under the Distribution Agreement will be made pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-296411) filed with the Securities and Exchange Commission (the “SEC”) on June 2, 2026, including a prospectus supplement relating to the offering of up to $17,350,000 of shares of Common Stock pursuant to the Distribution Agreement, subject to such Registration Statement being declared effective and other customary conditions.
The company filed a Form S-3 registration statement on June 2, 2026 to register the shares for this offering. Sales cannot commence until the SEC declares this registration statement effective, which is a standard regulatory requirement.
Event · Item 9.01 — Financial Statements and Exhibits
Plus Therapeutics entered into a Distribution Agreement with Canaccord Genuity LLC on June 1, 2026.
Added in current filing · verify on EDGAR →
Distribution Agreement, dated as of June 1, 2026, by and between Plus Therapeutics, Inc. and Canaccord Genuity LLC
Plus Therapeutics entered into a Distribution Agreement with Canaccord Genuity LLC effective June 1, 2026. This type of agreement typically establishes an at-the-market equity offering program allowing the company to sell shares through the broker over time. The full agreement was filed as an exhibit to a Form S-3 registration statement on June 2, 2026.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify